Circulating DNA for treatment and follow-up in squamous cell cancers
Recruiting
- Conditions
- squamous cell cancers
- Registration Number
- DRKS00031154
- Lead Sponsor
- Asklepios Tumorzentrum Hamburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Histopathologically verified SCC
Eligible for curatively or palliatively intended treatment
= 18 of years
Written and oral consent
Exclusion Criteria
Other cancer disease within 5 year of SCC diagnosis
Conditions that will contraindicate blood samples
Potential lack of compliance to standard FU program and study participation.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective is to investigate the clinical utility of circulating DNA assessments over the course of treatment and follow-up, by analyzing the correlation of the cfDNA (quantitative and molecular characteristics) to clinical outcome parameters including prognosis, elimination patterns<br>and recurrence.<br><br>The analysis of ctDNA is performed from the blood of the patient.<br><br>Blood samples are taken before starting therapy, during therapy and several times during follow-up. Depending on the treatment strategy, up to 10 samples are planned.
- Secondary Outcome Measures
Name Time Method Secondary objectives are to compare different methods for measuring circulating DNA in SCCs.